ArticleAmerican journal of translational research2025
Synergistic inhibition of glioblastoma by Furanodiene combined with Temozolomide and its immunological effects.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the antitumor activity of the natural compound Furanodiene in glioblastoma multiforme (GBM), evaluate its synergistic effect with temozolomide (TMZ), and assess its potential to enhance antitumor immune responses.
methodsLN229 and U251 glioma cells, as well as patient-derived glioma stem-like cells (GSCs), were treated with Furanodiene alone or in combination with TMZ. Cell proliferation, apoptosis, and neurosphere formation were evaluated
resultsFuranodiene inhibited cell proliferation and induced apoptosis in a dose-dependent manner. Combined treatment with TMZ further enhanced cytotoxicity and suppressed neurosphere formation.
conclusionsFuranodiene exerts potent antitumor effects and potentiates TMZ efficacy in GBM. Moreover, it enhances T cell activation and induces durable immune protection, supporting its potential as both a therapeutic and immunomodulatory agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.